⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 9, 2025The Journal of Headache and PainOpen Access

A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention

Jeremias Antinew Robert J. Fountaine Vittorio Loprinzo Esther Straghan Sergey Dubrovin Patrizia DeBesi Nick G. Vatakis Terence Fullerton

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the safety and tolerability of rimegepant for episodic migraine prevention.
Phase 4 open-label study design
Once-daily dosing of 75 mg
Duration of 24 weeks
Focus on safety and tolerability
Demonstrated overall safety profile
No serious adverse events reported
High tolerability in patients

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Open-label study assesses safety and tolerability of 75 mg rimegepant in episodic migraine prevention, suggesting favorable dosing outcomes.

Abstract

ClinicalTrials.gov NCT05207865 (registered January 12, 2022).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Antinew et al. (2025) studied this question.

synapsesocial.com/papers/69401d682d562116f28f90eb https://doi.org/10.1186/s10194-025-02225-7

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine2024 · 48 citations
2Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States2024 · 8 citations
3Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China2025 · 3 citations
4Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 studyRCT · 2026 · 1 citations
5Rimegepant for the acute treatment of migraine: a systematic review and meta-analysisMeta-Analysis · 2026 · 1 citations

More related papers

Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trials2026
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial2024
Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine2026

More from The Journal of Headache and Pain

SGLT-2 inhibitors and the risk of migraine in patients with type 2 diabetes mellitus: a population-based target trial emulation studySat,
Thermal vulnerability in migraine: thermosensory pathways, central sensitization and neuropeptide releaseWed,